Unreliable Survey Doesn't Sink Mucinex Fast-Max 'All In One' Claim In NAD Review
Executive Summary
RB didn't get help from consumer perception survey to support argument that "All In One" label statement is not claim the product treats all cold and flu symptoms. Council of Better Business Bureaus' division dismisses survey as faulty but approves RB's argument. NAD attorneys conclude 15- and 6-second TV and video "superhero 'movie trailer'” ads did not include "a sufficiently proximate and prominent list of symptoms" to counter "distracting features."
You may also be interested in...
Mucinex Fast-Max Advertising Claim Exceeds Indications In NAD Review
Review was second in two years by the Council of Better Business Bureaus' National Advertising Division of a challenge to Reckitt Benckiser ad claims for its Mucinex cough/cold line made by Procter & Gamble, which markets competing products including Vicks NyQuil and DayQuil brands.
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.